PTEN deletion is rare but often homogeneous in gastric cancer.
Related Research units
Abstract
Gastric carcinoma is the second most frequent cause of cancer-related death worldwide. As PTEN is a potential modifier of tumour response to trastuzumab, a recently approved therapy in metastatic HER2 positive gastric cancer, the existence of PTEN deletions in primary gastric cancer was investigated.
Bibliographical data
| Original language | English |
|---|---|
| Article number | 8 |
| ISSN | 0021-9746 |
| Publication status | Published - 2012 |
| pubmed | 22639407 |
|---|
